Sanofi : Volatility should make a big comeback

03/16/2023 | 02:35am EDT

long trade Target price hit

Entry price : 89.73€ | Target : 95€ | Stop-loss : 86€ | Potential : 5.87%

An exit from the recently observed accumulation phase to the upside could allow for the assumption that a clear upward trend is re-established with an increase in volatility. Investors have an opportunity to buy the stock and target the € 95.

Summary

• The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
• The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

• Before interest, taxes, depreciation and amortization, the company's margins are particularly high.

Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

The company is in a robust financial situation considering its net cash and margin position.

Over the past year, analysts have regularly revised upwards their sales forecast for the company.

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

• Revenue estimates are regularly revised downwards for the current and coming years.
• For the last few months, analysts have been revising downwards their earnings forecast.

© MarketScreener.com 2023

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.